Addiction-drug focused Indivior PLC yielded somewhat to competitive pressure on two fronts on July 11, withdrawing its earlier 2018 net revenue guidance of $1.13bn-$1.17bn, citing both generic competition for its opioid dependence product Suboxone (buprenorphine/naloxone sublingual film) and slow uptake of the recently launched Sublocade (injectable buprenorphine).
The UK-headquartered company said it can’t reliably provide revised net revenue guidance, but hopes to be able to do so...








